What’s Next For The International Pricing Index? Parsing A Strange US Senate Vote
Senate Finance drug pricing bill is moving forward, with two critical amendments defeated by 14-14 tie votes. One would have stripped the inflation penalty from the bill, which probably would have killed any bipartisan momentum. The second targeted the Medicare Part B International Pricing Index and was defeated by a truly surprising set of votes.
You may also be interested in...
In interview with the Pink Sheet, Jim Greenwood also worries about President Trump promoting drug pricing policies that could hinder innovation.
Former US FDA commissioner Scott Gottlieb doesn't "want to give too much away," but expresses skepticism about Trump administration's ability to implement its international price index proposal, noting there are ways for brand companies to game the system.
If nothing else, the purported draft may be a preview of what Democrats might do if they prevail in 2020. Proposal calls for HHS price negotiation, international reference pricing, price inflation rebates and structural Medicare Part D changes.